The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine

摘要: This randomized, blinded study evaluated the immunogenicity and safety of a booster dose Gardasil (qHPV) or Cervarix (bHPV) when administered to 12-13 year-old girls who were vaccinated at age 9-10 with 2 doses qHPV (0-6 months). 366 out 416 eligible participated in this follow-up study. Antibody titers measured just before one month post-booster. A Luminex Total IgG assay was used for antibody assessment results are presented Liminex Units (LU). Three years post-primary vaccination, 99-100% subjects had detectable antibodies 4HPV genotypes included GMTs varying from 50 322 LU depending on genotype. After qHPV, ≥4 fold increase vaccine observed 88-98% subjects. Post-booster varied 1666 4536 These 1.1 1.8-fold higher compared those post-second dose. bHPV, HPV16 HPV18 93-99% The anti-HPV16 5458 2665 LU, respectively. 1.2 1.8 than group (both P < 0.01). In bHPV 1.4-1.6-fold HPV6 HPV11was also (P 0.001). profile acceptable both vaccines. Both given as previously qHPV. magnitude immune response after is vaccine-dependent has same pattern that reported primary vaccination bHPV. When booster, vaccines have an profile. Longer studies warranted assess need doses.